Breaking News Instant updates and real-time market news.

PEP

PepsiCo

$122.50

-1.14 (-0.92%)

, ABT

Abbott

$76.23

-1.27 (-1.64%)

20:25
04/16/19
04/16
20:25
04/16/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include PepsiCo (PEP), consensus 92c... Abbott Laboratories (ABT), consensus 61c... U.S. Bancorp (USB), consensus $1... Morgan Stanley (MS), consensus $1.16... Bank of New York Mellon (BK), consensus 96c... Textron (TXT), consensus 68c.

PEP

PepsiCo

$122.50

-1.14 (-0.92%)

ABT

Abbott

$76.23

-1.27 (-1.64%)

USB

U.S. Bancorp

$50.20

0.3 (0.60%)

MS

Morgan Stanley

$47.03

0.95 (2.06%)

BK

BNY Mellon

$53.45

0.87 (1.65%)

TXT

Textron

$52.30

0.88 (1.71%)

  • 16

    Apr

  • 17

    Apr

  • 17

    Apr

  • 17

    Apr

  • 17

    Apr

  • 17

    Apr

  • 17

    Apr

  • 24

    Apr

  • 26

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 06

    May

  • 08

    May

  • 18

    May

  • 29

    May

  • 11

    Jun

PEP PepsiCo
$122.50

-1.14 (-0.92%)

04/11/19
MSCO
04/11/19
DOWNGRADE
Target $24
MSCO
Underweight
Morgan Stanley downgrades Keurig Dr Pepper to Underweight on coffee risk
As previously reported, Morgan Stanley analyst Dara Mohsenian downgraded Keurig Dr Pepper to Underweight from Equal Weight as he sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. Based on the firm's recent AlphaWise survey, the analyst sees risk to coffee growth, noting that his forecast of around 1.5% is below the market-implied 4% long-term coffee topline growth, which is a key driver of his EPS forecast by 2021 being 5% below consensus. Additionally, Keurig Dr Pepper shares trade at a premium to the average of beverage peers Coca-Cola (KO) and PepsiCo (PEP) despite lower expected long-term topline growth, Mohsenian noted. He cut his price target on Keurig Dr Pepper shares to $24 from $27.
03/11/19
STFL
03/11/19
NO CHANGE
Target $67
STFL
Buy
Hypothetical Bang sale more negative than positive for Monster, says Stifel
Stifel analyst Mark Astrachan examined the hypothetical impact on Monster Beverage (MNST) should a larger beverages competitor acquire Bang, though he noted he has no knowledge of M&A negotiations or discussions with the energy drink competitor. He ultimately concluded a potential acquisition of Bang would be more negative than positive for Monster, though he also noted that risks of an acquisition include potential disruption of Bang's recent momentum, especially if it were to be acquired by PepsiCo (PEP) and transition distribution most likely in-house from the AB InBev (BUD) system. Additionally, a theoretical Bang deal could accelerate a decision by Coca-Cola (KO) regarding acquiring, or not, the remaining shares in Monster it does not currently own, said Astrachan, who keeps a Buy rating and $67 price target on Monster Beverage shares.
03/07/19
03/07/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Five Below (FIVE) initiated with an Outperform at Oppenheimer. 2. Teva (TEVA) reinstated with a Buy at UBS. 3. Chiasma (CHMA) initiated with an Overweight at Cantor Fitzgerald. 4. Monster Beverage (MNST) and Constellation Brands (STZ) were initiated with an Outperform at Credit Suisse, while Procter & Gamble (PG), Coca-Cola (KO), and Church & Dwight (CHD) were initiated with a Neutral, and PepsiCo (PEP), Colgate-Palmolive (CL), and Clorox (CLX) initiated with an Underperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/19
FBCO
03/07/19
INITIATION
FBCO
Credit Suisse starts Household Products & Beverages with Constellation top pick
Credit Suisse analyst Kaumil Gajrawala rolled out coverage last night on eight names in the Household Products & Beverages space. The analyst's ratings consist of three Outperforms, two Underperforms, and three Neutrals. His top pick is Constellation Brands (STZ), which he started with an Outperform rating and $230 price target. The company offers "predictable" high-single digit revenue growth with a valuation that is "well below slower growth peers," Gajrawala tells investors in a research note. His other Outperform ratings are on Monster Beverage (MNST) and Clorox (CLX). The analyst has a $78 price target on Monster, noting it is the fastest growing company in his coverage "with runway for continued growth." He has a $172 price target on Clorox saying the company's "unique" portfolio position justifies a premium valuation. Gajrawala's Neutral rated names are Church & Dwight (CHD), Procter & Gamble (PG) and Coca-Cola (KO). His two Underperforms are PepsiCo (PEP) and Colgate-Palmolive (CL). PepsiCo has a $100 price target as the analyst sees limited upside amid the company's "stepped-up" investment years. Colgate-Palmolive, Gajrawala's less favorite name, has a $55 price target. The company's out-year margins are at risk as it reinvests to address several years of slowing growth and sales declines, Gajrawala contends.
ABT Abbott
$76.23

-1.27 (-1.64%)

04/15/19
RBCM
04/15/19
NO CHANGE
Target $82
RBCM
Sector Perform
Abbott price target raised to $82 from $77 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Abbott to $82 ahead of its Q1 results, saying the "pattern of revenue growth" seen last year should continue this quarter as Core Laboratory, Electrophysiology, Structural Heart, and Diabetes Care product categories "lead the way." The analyst also expects Abbott's organic revenue growth in the Medical Devices segment to come at the high end of guidance, adding that while his new price target implies a multiple of 22.5-times vs. peer group's 21-times, he believes that the company's growth profile justifies the valuation premium. Henry recommends that investors buy the stock on "any weakness".
04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.
03/26/19
PIPR
03/26/19
NO CHANGE
Target $165
PIPR
Overweight
Piper discusses 16% selloff in DexCom over past three trading days
Piper Jaffray analyst JP McKim says he's fielded a lot of investor questions with shares of DexCom (DXCM) down 16% over the last three trading days. The crux of the selloff is Abbott's (ABT) Libre 2.0 and whether it gets interoperable continuous glucose monitoring and if so, what that does to volumes and price, McKim tells investors in a research note. The analyst sees little risk to DexCom's volumes for given the market inflection for continuous glucose monitoring, but adds that if Libre gets iCGM "payers maybe push a little harder on price." McKim admits that "headline risk is building around the approval" but keeps an Overweight rating on DexCom shares with a $165 price target. Libre 2.0 getting iCGM is not fully priced in the stock at this point, but some of that risk certainly is, says McKim.
03/22/19
BMOC
03/22/19
NO CHANGE
Target $204
BMOC
Outperform
Edwards Lifesciences price target raised to $204 from $190 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Edwards Lifesciences (EW) to $204 and kept her Outperform rating while removing the stock from her Top Picks list after its 25% year-to-date run-up. While there are some mid-year catalysts for the company such as the outcomes from the CMS NationalCoverage Decision proposal on March 27, clinical data from Pascal, and patent litigation with Abbott (ABT) regarding Pascal, the analyst contends that some consolidation in the stock price would not be surprising.
USB U.S. Bancorp
$50.20

0.3 (0.60%)

01/28/19
BARD
01/28/19
DOWNGRADE
Target $55
BARD
U.S. Bancorp downgraded to Neutral following recent rally at Baird
As reported previously, Baird analyst David George downgraded U.S. Bancorp to Neutral from Outperform. The analyst cited its recent rally and outperformance of the banking index relative to the market. He said the risk/reward is now more balanced and noted that the stock trades at a slight premium to peers. George maintained his $55 price target on U.S. Bancorp shares.
01/28/19
01/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autohome (ATHM) downgraded to Underweight from Neutral at JPMorgan with analyst Binbin Ding saying he expects the company to see weakened pricing power amid a "challenging" market environment. 2. Vale (VALE) downgraded to Hold from Buy at HSBC and Jefferies, to Neutral from Outperform at Macquarie, and to Market Perform from Outperform at BMO Capital. 3. Amgen (AMGN) downgraded to In Line from Outperform at Evercore ISI with analyst Umer Raffat citing increased biosimilar competition and an imminent court decision on Enbrel patents with Sandoz. 4. Dynagas LNG (DLNG) downgraded to Neutral from Buy at B. Riley FBR with analyst Liam Burke saying the company "significantly" reduced its cash distribution in order to strengthen its balance sheet. 5. SunTrust (STI) and U.S. Bancorp (USB) were downgraded to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/19
02/08/19
NO CHANGE

Odeon's Bove says buy SunTrust, Midwest banks after deal announcement
Odeon analyst Dick Bove recommends investors buy shares of SunTrust (STI) following the company's announcement of an agreement to merge with BB&T (BBT), stating that the deal is expected to be accretive by 2021, but likely to be dilutive before this time. He also thinks investors should consider buying a group of Midwestern banks, as the deal puts "significant pressure" on those banks to merge. Banks such as Fifth Third (FITB) and KeyCorp (KEY) "need to join forces," while PNC (PNC) and U.S. Bancorp (USB) "need to buy more scale," Bove stated in his research note.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
MS Morgan Stanley
$47.03

0.95 (2.06%)

04/16/19
BMOC
04/16/19
NO CHANGE
Target $260
BMOC
Market Perform
Goldman Sachs price target lowered to $260 from $262 at BMO Capital
BMO Capital analyst James Fotheringham lowered his price target on Goldman Sachs (GS) to $260 and kept his Market Perform rating after its Q1 results. The analyst says that in spite of the company's "broad-based beat", he is lowering his FY20 EPS view to $27.06 from $27.66 due to lower expected Investing and Lending net revenues along with higher credit provisions. Fotheringham prefers Morgan Stanley (MS) to Goldman Sachs since the two trade at a similar two-year-forward rolling earnings multiple, but the wealth management-oriented earnings mix of the former implies a premium that he expects to materialize.
02/01/19
02/01/19
DOWNGRADE

Sell
Societe Generale downgrades Goldman Sachs, Morgan Stanley to Sell
As previously reported, Societe Generale analyst Andrew Lim downgraded Goldman Sachs (GS) and Morgan Stanley (MS), both to Sell from Hold, citing his view that the credit cycle deterioration "has already been set in motion" and that it will pay to be defensive for the rest of 2019. Goldman and Morgan are much more exposed to pressure on market-sensitive revenues as purer investment banks, Lim tells investors. He does not have any Buy ratings on big U.S. banks, but continues to favor holding positions in Bank of America (BAC) and JP Morgan (JPM), which Lim views as the most defensive large cap U.S. banks, he tells investors.
02/01/19
SOCG
02/01/19
DOWNGRADE
SOCG
Sell
Morgan Stanley downgraded to Sell from Hold at Societe Generale
Societe Generale analyst Andrew Lim downgraded Morgan Stanley to Sell from Hold.
BK BNY Mellon
$53.45

0.87 (1.65%)

10/19/18
KBWI
10/19/18
DOWNGRADE
Target $49
KBWI
Underperform
BNY Mellon downgraded to Underperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl downgraded BNY Mellon to Underperform and lowered his price target for the shares to $49 from $55. While the company beat estimates this quarter, several line items were weaker than expectations, Kleinhanzl tells investors in a research note. He cut his 2019 and 2020 estimates again as a result of limited upside and limited visibility into BNY Mellon's earnings power.
10/19/18
10/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Las Vegas Sands (LVS) downgraded to Buy from Conviction Buy at Goldman Sachs. 2. eBay (EBAY) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying PayPal's (PYPL) earnings release last night suggested weak eBay gross merchandise volume trends in Q3. 3. Ford (F) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Adam Jonas saying he now believes the market needs more evidence of success before embracing the Ford restructuring story. 4. BNY Mellon (BK) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying while the company beat estimates this quarter, several line items were weaker than expectations. 5. Harley-Davidson (HOG) downgraded to Market Perform from Outperform at BMO Capital with analyst Gerrick Johnson saying his previously expected catalysts for sales and earnings did not materialize. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/19
JEFF
01/08/19
DOWNGRADE
Target $91
JEFF
Hold
Jefferies cuts trust bank estimates, downgrades Northern Trust to Hold
Jefferies analyst Ken Usdin downgraded Northern Trust (NTRS) to Hold from Buy and lowered his price target for the shares to $91 from $121. The sharp Q4 decline in market levels weighs on trust banks' revenue estimates, Usdin tells investors in a research note. He downgraded Northern Trust with his 2020 earnings estimate now 7% below consensus. Trust bank valuations remain below historical averages, but slower organic growth and "less macro help" are challenges, says the analyst. He also lowered his price target for Hold-rated BNY Mellon (BK) to $50 and Hold-rated State Street (STT) to $70.
01/09/19
SBSH
01/09/19
DOWNGRADE
Target $52
SBSH
Neutral
BNY Mellon downgraded to Neutral from Buy at Citi
Citi analyst Keith Horowitz downgraded BNY Mellon to Neutral with a $52 price target. The analyst believes the company's valuation relative to peers has gotten full and says he cannot justify a strong case for 15% plus upside from current levels. He views BK as fairly valued at current prices.
TXT Textron
$52.30

0.88 (1.71%)

01/10/19
SUSQ
01/10/19
INITIATION
Target $52
SUSQ
Neutral
Textron initiated with a Neutral at Susquehanna
Susquehanna analyst Charles Minervino initiated Textron with a Neutral rating as its largest business, Textron Aviation, is in the midst of what will likely be a multi-year upcycle in business jet orders. Coupled with new product launches, the cycle should be an attractive tailwind for orders revenue growth and margin expansion. However, he believes the potential large-scale orders in Aviation and Bell are at least partially factored in already and notes that his 2019-2020 EPS estimates are slightly below consensus. Minervino has a $52 price target on Textron shares.
04/01/19
FBCO
04/01/19
INITIATION
FBCO
Neutral
Textron initiated with a Neutral at Credit Suisse
04/01/19
04/01/19
INITIATION
Target $50

Neutral
Textron started with Neutral at Credit Suisse on strong positions, mixed markets
As previously reported, Credit Suisse analyst Robert Spingarn initiated coverage of Textron with a Neutral rating and a $50 price target. The analyst notes that Textron is a market leader in many of its markets, including executive aviation, commercial rotorcraft, and specialized vehicles. However, many of these markets have low visibility and/or soft growth, which often require competitive pricing as well as continual product investment, he contended.
01/08/19
JEFF
01/08/19
NO CHANGE
Target $59
JEFF
Buy
Textron removed from Franchise Pick list at Jefferies
Jefferies analyst Sheila Kahyaoglu removed Textron from her firm's Franchise Pick list and lowered her price target for the shares to $59 from $68. The analyst continues to like Textron's potential to capture market share, but she believes consensus forecasts are likely too high for 2019. Kahyaoglu keeps a Buy rating on Textron.

TODAY'S FREE FLY STORIES

ACDVF

Air Canada

$0.00

(0.00%)

, BA

Boeing

$380.02

2.48 (0.66%)

17:10
04/18/19
04/18
17:10
04/18/19
17:10
Periodicals
Air Canada says will review plane systems on Boeing's MAX, Reuters says »

Air Canada (ACDVF) said…

ACDVF

Air Canada

$0.00

(0.00%)

BA

Boeing

$380.02

2.48 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    Apr

  • 29

    May

  • 05

    Jun

CYCN

Cyclerion Therapeutics

$15.57

-0.68 (-4.18%)

17:08
04/18/19
04/18
17:08
04/18/19
17:08
Syndicate
Breaking Syndicate news story on Cyclerion Therapeutics »

Cyclerion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$39.37

-0.5 (-1.25%)

, LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

17:07
04/18/19
04/18
17:07
04/18/19
17:07
Hot Stocks
Pfizer, Lilly say tanezumab met 2/3 co-primary endpoints in Phase 3 study »

Pfizer Inc. (PFE) and Eli…

PFE

Pfizer

$39.37

-0.5 (-1.25%)

LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

FAST

Fastenal

$71.08

0.95 (1.35%)

17:06
04/18/19
04/18
17:06
04/18/19
17:06
Hot Stocks
Fastenal approves two-for-one stock split »

Fastenal Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 05

    Jun

AKRX

Akorn

$2.77

-0.16 (-5.46%)

, IQV

Iqvia

$133.02

0.76 (0.57%)

17:02
04/18/19
04/18
17:02
04/18/19
17:02
Hot Stocks
Akorn gets FDA approval for Loteprednol Etabonate Ophthalmic »

Akorn (AKRX) announced…

AKRX

Akorn

$2.77

-0.16 (-5.46%)

IQV

Iqvia

$133.02

0.76 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 07

    May

  • 05

    Jun

  • 23

    Jun

ATR

AptarGroup

$108.21

0.41 (0.38%)

17:01
04/18/19
04/18
17:01
04/18/19
17:01
Hot Stocks
AptarGroup raises dividend 6%, announces new $350M share repurchase plan »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 07

    May

BBY

Best Buy

$73.65

0.24 (0.33%)

17:00
04/18/19
04/18
17:00
04/18/19
17:00
Hot Stocks
Best Buy CEO Joly sells 171,711 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

16:59
04/18/19
04/18
16:59
04/18/19
16:59
Hot Stocks
Intuitive Surgical tightens FY19 procedure growth view to 15%-17% from 13%-17% »

Sees FY19 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 25

    Apr

  • 03

    May

BHB

Bar Harbor Bankshares

$25.71

-0.42 (-1.61%)

16:58
04/18/19
04/18
16:58
04/18/19
16:58
Hot Stocks
Bar Harbor Bankshares raises quarterly dividend 10% to 22c per share »

Bar Harbor Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

, EA

Electronic Arts

$93.13

1.19 (1.29%)

16:55
04/18/19
04/18
16:55
04/18/19
16:55
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

EA

Electronic Arts

$93.13

1.19 (1.29%)

GME

GameStop

$8.78

-0.15 (-1.68%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$90.73

0.97 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 02

    May

  • 07

    May

  • 13

    May

  • 29

    May

  • 13

    Nov

SCOR

comScore

$12.91

-0.38 (-2.86%)

16:46
04/18/19
04/18
16:46
04/18/19
16:46
Hot Stocks
comScore names Kathy Bachmann as COO, effective April 17 »

On April 12, the Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

SRE

Sempra Energy

$127.42

0.1 (0.08%)

16:46
04/18/19
04/18
16:46
04/18/19
16:46
Hot Stocks
Sempra Energy receives FERC authorization for Texas project »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 21

    May

SPR

Spirit AeroSystems

$85.57

-0.12 (-0.14%)

, BA

Boeing

$380.02

2.48 (0.66%)

16:45
04/18/19
04/18
16:45
04/18/19
16:45
Hot Stocks
Boeing, Spirit Aero reach pact to cover production costs for B737 program »

According to a regulatory…

SPR

Spirit AeroSystems

$85.57

-0.12 (-0.14%)

BA

Boeing

$380.02

2.48 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 29

    May

  • 05

    Jun

16:45
04/18/19
04/18
16:45
04/18/19
16:45
General news
Treasury Market Summary: »

Treasury Market Summary:…

16:40
04/18/19
04/18
16:40
04/18/19
16:40
General news
Fed Balance Sheet Level data reported »

Week of 4/17 Fed Balance…

16:40
04/18/19
04/18
16:40
04/18/19
16:40
General news
Money Supply M2 Weekly Change data reported »

Week of 4/8 Money Supply…

BLK

BlackRock

$465.67

-1.99 (-0.43%)

16:38
04/18/19
04/18
16:38
04/18/19
16:38
Hot Stocks
BlackRock CFO sells 2,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 27

    Oct

TRV

Travelers

$138.82

2.93 (2.16%)

, HON

Honeywell

$169.01

6.09 (3.74%)

16:38
04/18/19
04/18
16:38
04/18/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Thursday »

The S&P 500 notched a…

TRV

Travelers

$138.82

2.93 (2.16%)

HON

Honeywell

$169.01

6.09 (3.74%)

AXP

American Express

$113.67

1.89 (1.69%)

PM

Philip Morris

$84.53

-0.96 (-1.12%)

ZM

Zoom Video

$62.00

(0.00%)

PINS

Pinterest

$24.46

(0.00%)

CGC

Canopy Growth

$44.43

1.6 (3.74%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

FB

Facebook

$178.28

-0.49 (-0.27%)

BX

Blackstone

$38.65

2.74 (7.63%)

ADTN

Adtran

$16.60

2.055 (14.13%)

URI

United Rentals

$136.05

10.25 (8.15%)

CHKP

Check Point

$120.01

-9.56 (-7.38%)

SNBR

Sleep Number

$39.23

-8.76 (-18.25%)

SKX

Skechers

$31.60

-3.68 (-10.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 24

    Apr

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 14

    May

  • 14

    May

  • 15

    May

  • 17

    May

  • 18

    May

  • 03

    Jun

  • 05

    Jun

  • 11

    Jun

  • 13

    Nov

  • 18

    Apr

  • 18

    Apr

GBCI

Glacier Bancorp

$41.70

-0.7 (-1.65%)

16:36
04/18/19
04/18
16:36
04/18/19
16:36
Earnings
Glacier Bancorp reports Q1 EPS 58c, consensus 58c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 24

    Apr

BLMN

Bloomin' Brands

$19.24

0.42 (2.23%)

16:34
04/18/19
04/18
16:34
04/18/19
16:34
Recommendations
Bloomin' Brands analyst commentary at Tigress Financial »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 30

    Apr

APHA

Aphria

$7.65

-0.165 (-2.11%)

16:32
04/18/19
04/18
16:32
04/18/19
16:32
Hot Stocks
Aphria subsidiary secures cannabis cultivation license in Germany »

Aphria Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$30.29

0.28 (0.93%)

, SO

Southern Company

$51.95

-0.22 (-0.42%)

16:32
04/18/19
04/18
16:32
04/18/19
16:32
Hot Stocks
CenterPoint Energy names Xia Liu as CFO, effective April 22 »

CenterPoint Energy (CNP)…

CNP

CenterPoint Energy

$30.29

0.28 (0.93%)

SO

Southern Company

$51.95

-0.22 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

  • 09

    May

  • 21

    May

  • 21

    May

BANF

BancFirst

$55.58

-0.34 (-0.61%)

16:30
04/18/19
04/18
16:30
04/18/19
16:30
Earnings
BancFirst reports Q1 EPS 96c, consensus 92c »

At March 31, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
04/18/19
04/18
16:30
04/18/19
16:30
Options
Preliminary option volume of 20.4M today »

Preliminary option volume…

ZSAN

Zosano Pharma

$3.41

-0.11 (-3.13%)

16:28
04/18/19
04/18
16:28
04/18/19
16:28
Hot Stocks
Zosano Pharma CEO buys 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.